European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis

J.-M. Dumonceau; A. Andriulli; J. Deviere; A. Mariani; J. Rigaux; T. H. Baron; P. A. Testoni

doi:10.1055/s-0029-1244208

Endoscopy, Table of Contents

Endoscopy 2010; 42(6): 503-515
DOI: 10.1055/s-0029-1244208

Guidelines

European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis

J.-M. Dumonceau¹ , A. Andriulli² , J. Deviere³ , A. Mariani⁴ , J. Rigaux³ , T. H. Baron⁵ , P. A. Testoni⁴

¹Service of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland
²Division of Gastroenterology, Casa Sollievo Sofferemza Hospital, IRCCS, San Giovanni Rotondo, Italy
³Departments of Gastroenterology and Hepato-Pancreatology, Erasme University Hospital, Brussels, Belgium
⁴Division of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy
⁵Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Medical Center, Rochester, Minnesota, USA

Abstract

Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). Risk factors for post-ERCP pancreatitis (PEP) are both patient-related and procedure-related. Identification of patients at high risk for PEP is important in order to target prophylactic measures. Prevention of PEP includes administration of nonsteroidal inflammatory drugs (NSAIDs), use of specific cannulation techniques, and placement of temporary pancreatic stents. The aim of this guideline commissioned by the European Society of Gastrointestinal Endoscopy (ESGE) is to provide practical, graded, recommendations for the prevention of PEP.

Full Text

References

1 Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001; 323 334-336
2 Freeman M L, Nelson D B, Sherman S. et al . Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996; 335 909-918
3 Choi C W, Kang D H, Kim G H. et al . Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009; 69 e11-e18
4 Lee K T, Lee D H, Yoo B M. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2008; 37 445-448
5 Cotton P B, Lehman G, Vennes J. et al . Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991; 37 383-393
6 Bradley E L. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992: Arch Surg. 1993; 128 586-590
7 Testoni P A, Caporuscio S, Bagnolo F, Lella F. Twenty-four-hour serum amylase predicting pancreatic reaction after endoscopic sphincterotomy. Endoscopy. 1999; 31 131-136
8 Bretthauer M, Seip B, Aasen S. et al . Carbon dioxide insufflation for more comfortable endoscopic retrograde cholangiopancreatography: a randomized, controlled, double-blind trial. Endoscopy. 2007; 39 58-64
9 Andriulli A, Loperfido S, Napolitano G. et al . Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102 1781-1788
10 Masci E, Mariani A, Curioni S, Testoni P A. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003; 35 830-834
11 Freeman M L, DiSario J A, Nelson D B. et al . Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54 425-434
12 Loperfido S, Angelini G, Benedetti G. et al . Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998; 48 1-10
13 Masci E, Toti G, Mariani A. et al . Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001; 96 417-423
14 Williams E J, Taylor S, Fairclough P. et al . Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy. 2007; 39 793-801
15 Harewood G C, Pochron N L, Gostout C J. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc. 2005; 62 367-370
16 Norton I D, Gostout C J, Baron T H. et al . Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc. 2002; 56 239-243
17 Fazel A, Quadri A, Catalano M F, Meyerson S M, Geenen J E. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc. 2003; 57 291-294
18 Smithline A, Silverman W, Rogers D. et al . Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc. 1993; 39 652-657
19 Tarnasky P R, Palesch Y Y, Cunningham J T. et al . Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology. 1998; 115 1518-1524
20 Andriulli A, Forlano R, Napolitano G. et al . Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion. 2007; 75 156-163
21 Williams E J, Taylor S, Fairclough P. et al . Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut. 2007; 56 821-829
22 Varadarajulu S, Kilgore M L, Wilcox C M, Eloubeidi M A. Relationship among hospital ERCP volume, length of stay, and technical outcomes. Gastrointest Endosc. 2006; 64 338-347
23 Allison M C, Ramanaden D N, Fouweather M G, Davis D K, Colin-Jones D G. Provision of ERCP services and training in the United Kingdom. Endoscopy. 2000; 32 693-699
24 Hilsden R J, Romagnuolo J, May G R. Patterns of use of endoscopic retrograde cholangiopancreatography in a Canadian province. Can J Gastroenterol. 2004; 18 619-624
25 Colton J, Curran C. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc. 2009; 70 457-467
26 Rabenstein T, Roggenbuck S, Framke B. et al . Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?. Gastrointest Endosc. 2002; 55 476-483
27 Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman G A. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol. 1996; 91 1553-1557
28 Testoni P A, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc. 2001; 53 33-39
29 Kapetanos D, Kokozidis G, Kinigopoulou P. et al . The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepato-Gastroenterol. 2007; 54 556-560
30 Thomas P R, Sengupta S. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastroenterol Hepatol. 2001; 16 923-926
31 Ito K, Fujita N, Noda Y. et al . Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterol. 2007; 13 3855-3860
32 Dai H-F, Wang X-W, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2009; 8 11-16
33 Elmunzer B, Waljee A, Elta G. et al . A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008; 57 1262
34 Zheng M-H, Xia H, Chen Y-P. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut. 2008; 57 1632
35 Bang U C, Nojgaard C, Andersen P K, Matzen P. Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther. 2009; 29 1078-1085
36 Shao L M, Chen Q Y, Chen M Y, Cai J T. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci. 2010; 55 1-7
37 Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg. 2001; 5 339-345; discussion 345
38 Andriulli A, Clemente R, Solmi L. et al . Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002; 56 488-495
39 Andriulli A, Solmi L, Loperfido S. et al . Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004; 2 713-718
40 Arvanitidis D, Anagnostopoulos G K, Giannopoulos D. et al . Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004; 19 278-282
41 Benvenutti S, Zancanella L, Piazzi L. et al . Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesylate: A randomized placebo controlled multicenter study. Dig Liv Dis. 2006; 38 S15
42 Bordas J M, Toledo-Pimentel V, Llach J. et al . Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998; 47 230-234
43 Persson B, Slezak P, Efendic S, Haggmark A. Can somatostatin prevent injection pancreatitis after ERCP?. Hepatogastroenterology. 1992; 39 259-261
44 Poon R T, Yeung C, Liu C L. et al . Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut. 2003; 52 1768-1773
45 Poon R T, Yeung C, Lo C M. et al . Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999; 49 593-598
46 Saari A, Kivilaakso E, Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm. 1988; 2 271-278
47 Arcidiacono R, Gambitta P, Rossi A. et al . The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994; 26 715-718
48 Duvnjak M, Supanc V, Simicevic V N. et al . Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica. 1999; 53 115-118
49 Hardt P D, Kress O, Fadgyas T. et al . Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res. 2000; 5 165-170
50 Li Z S, Pan X, Zhang W J. et al . Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2007; 102 46-51
51 Manolakopoulos S, Avgerinos A, Vlachogiannakos J. et al . Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc. 2002; 55 470-475
52 Sternlieb J M, Aronchick C A, Retig J N. et al . A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992; 87 1561-1566
53 Testoni P A, Bagnolo F, Andriulli A. et al . Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001; 15 965-972
54 Thomopoulos K C, Pagoni N A, Vagenas K A. et al . Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc. 2006; 64 726-731
55 Cavallini G, Tittobello A, Frulloni L. et al . Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy – Italian Group. N Engl J Med. 1996; 335 919-923
56 Manes G, Ardizzone S, Lombardi G. et al . Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc. 2007; 65 982-987
57 Xiong G S, Wu S M, Zhang X W, Ge Z Z. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res. 2006; 39 85-90
58 Fujishiro H, Adachi K, Imaoka T. et al . Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006; 21 1065-1069
59 Tsujino T, Komatsu Y, Isayama H. et al . Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005; 3 376-383
60 Ueki T, Otani K, Kawamoto K. et al . Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol. 2007; 42 161-167
61 Yoo J W, Ryu J K, Lee S H. et al . Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas. 2008; 37 366-370
62 Bai Y, Gao J, Shi X, Zou D, Li Z. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology. 2008; 8 504-509
63 Zheng M, Bai J, Yuan B. et al . Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008; 8 6
64 Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy. 2004; 36 170-173
65 Matsushita M, Takakuwa H, Shimeno N. et al . Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol. 2009; 44 71-75
66 Schwartz J J, Lew R J, Ahmad N A. et al . The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc. 2004; 59 179-184
67 Prat F, Amaris J, Ducot B. et al . Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc. 2002; 56 202-208
68 Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion. 1993; 54 105-111
69 Bai Y, Gao J, Zhang W, Zou D, Li Z. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther. 2008; 28 557-564
70 Zheng M, Chen Y, Bai J. et al . Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2008; 37 247-253
71 Andriulli A, Annese V. Risk of post-endoscopic retrograde cholangiopancreatography pancreatitis and ways to prevent it: old myths, a current need? The case of allopurinol. Clin Gastroenterol Hepatol. 2008; 6 374-376
72 Katsinelos P, Kountouras J, Paroutoglou G. et al . Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005; 62 105-111
73 Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol. 2006; 12 3751-3755
74 Lavy A, Karban A, Suissa A. et al . Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas. 2004; 29 e45-e50
75 Barkay O, Niv E, Santo E. et al . Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc. 2008; 22 1971-1976
76 Rabenstein T, Fischer B, Wiessner V. et al . Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004; 59 606-613
77 Deviere J, Le Moine O, Van Laethem J L. et al . Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology. 2001; 120 498-505
78 Dumot J A, Conwell D L, Zuccaro Jr G. et al . A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol. 2001; 96 2098-2102
79 Sherman S, Cheng C L, Costamagna G. et al . Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009; 38 267-274
80 Sherman S, Cheng C-L, Costamagna G. et al . Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009; 38 267-274
81 Kapetanos D, Kokozidis G, Christodoulou D. et al . A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc. 2007; 66 513-518
82 Sherman S, Alazmi W M, Lehman G A. et al . Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointest Endosc. 2009; 69 462-472
83 van Westerloo D J, Rauws E A, Hommes D. et al . Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc. 2008; 68 246-254
84 Terruzzi V, Radaelli F, Meucci G, Minoli G. Is the supine position as safe and effective as the prone position for endoscopic retrograde cholangiopancreatography? A prospective randomized study. Endoscopy. 2005; 37 1211-1214
85 Tringali A, Mutignani M, Milano A, Perri V, Costamagna G. No difference between supine and prone position for ERCP in conscious sedated patients: a prospective randomized study. Endoscopy. 2008; 40 93-97
86 Vandervoort J, Soetikno R M, Tham T CK. et al . Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002; 56 652-656
87 Cheon Y K, Cho K B, Watkins J L. et al . Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc. 2007; 65 385-393
88 George S, Kulkarni A A, Stevens G, Forsmark C E, Draganov P. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci. 2004; 49 503-508
89 Keswani R, Hovis R, Edmunowicz S. et al . Carbon dioxide (CO₂) insufflation during ERCP for the reduction of post-procedure pain: preliminary results of a randomized, double-blind controlled trial. Gastrointest Endosc. 2008; 67 AB107
90 Maple J T, Keswani R N, Hovis R M. et al . Carbon dioxide insufflation during ERCP for reduction of postprocedure pain: a randomized, double-blind, controlled trial. Gastrointest Endosc. 2009; 70 278-283
91 Cennamo V, Fuccio L, Zagari R M. et al . Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009; 104 2343-2350
92 Choudhary A, Puli S, Ibdah J, Bechtold M. Guidewire use for prevention of post ERCP pancreatitis: a meta-analysis of randomized controlled trials. Gastrointest Endosc. 2009; 69 AB305
93 Madhoun M, Te C, Stoner J, Maple J. Does wire-guided cannulation prevent post-ERCP pancreatitis? A meta-analysis. Gastrointest Endosc. 2009; 69 AB132
94 Cheung J, Tsoi K K, Quan W-L, Lau J YW, Sung J JY. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc. 2009; 70 1211-1219
95 Verma D, Kapadia A, Adler D G. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc. 2007; 66 283-290
96 Herreros de Tejada A, Calleja J L, Díaz G. et al . Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. Gastrointest Endosc. 2009; 70 700-709
97 Maeda S, Hayashi H, Hosokawa O. et al . Prospective randomized pilot trial of selective biliary cannulation using pancreatic guide-wire placement. Endoscopy. 2003; 35 721-724
98 Ito K, Fujita N, Noda Y. et al . Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. Endoscopy. 2008; 40 (Suppl 1) A17
99 Nguyen-Tang T, Dumonceau J M. Double-guidewire technique for difficult bile duct cannulation: why not insert a prophylactic pancreatic stent?. Gastrointest. Endosc 2010; in press
100 Iqbal S, Sharma P, Shah S. Role of double guide wire cannulation during ERCP. Gastrointest Endosc. 2008; 67 AB158
101 Ito K, Fujita N, Noda Y. et al . Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography. World J Gastroenterol. 2008; 14 5595-5600; discussion 5599
102 Patel S, Torres V, Gross G. The early use of the double-wire technique to facilitate difficult biliary cannulation and its impact on post-ERCP pancreatitis. Gastrointest Endosc. 2009; 69 AB159
103 Gyökeres T, Duhl J, Varsányi M. et al . Double guide wire placement for endoscopic pancreaticobiliary procedures. Endoscopy. 2003; 35 95-96
104 Cennamo V, Fuccio L, Repici A. et al . Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study. Gastrointest Endosc. 2009; 69 473-479
105 Wang P, Li Z-S, Liu F. et al . Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009; 104 31-40
106 Akaraviputh T, Lohsiriwat V, Swangsri J. et al . The learning curve for safety and success of precut sphincterotomy for therapeutic ERCP: a single endoscopist’s experience. Endoscopy. 2008; 40 513-516
107 Fukatsu H, Kawamoto H, Harada R. et al . Quantitative assessment of technical proficiency in performing needle-knife precut papillotomy. Surg Endosc. 2009; 23 2066-2072
108 Harewood G C, Baron T H. An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol. 2002; 97 1708-1712
109 Manes G, Di Giorgio P, Repici A. et al . An analysis of the factors associated with the development of complications in patients undergoing precut sphincterotomy: a prospective, controlled, randomized, multicenter study. Am J Gastroenterol. 2009; 104 2412-2417
110 de Weerth A, Seitz U, Zhong Y. et al . Primary precutting versus conventional over-the-wire sphincterotomy for bile duct access: a prospective randomized study. Endoscopy. 2006; 38 1235-1240
111 Tang S-J, Haber G B, Kortan P. et al . Precut papillotomy versus persistence in difficult biliary cannulation: a prospective randomized trial. Endoscopy. 2005; 37 58-65
112 Yasuda I, Tomita E, Enya M, Kato T, Moriwaki H. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function?. Gut. 2001; 49 686-691
113 Baron T H, Harewood G C. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol. 2004; 99 1455-1460
114 Weinberg B M, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev. 2006; CD004890
115 DiSario J A, Freeman M L, Bjorkman D J. et al . Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology. 2004; 127 1291-1299
116 Attasaranya S, Cheon Y, Vittal H. et al . Large-diameter biliary orifice balloon dilation to aid in endoscopic bile duct stone removal: a multicenter series. Gastrointest Endosc. 2008; 67 1046-1052
117 Ersoz G, Tekesin O, Ozutemiz A O, Gunsar F. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc. 2003; 57 156-159
118 Maydeo A, Bhandari S. Balloon sphincteroplasty for removing difficult bile duct stones. Endoscopy. 2007; 39 958-961
119 Minami A, Hirose S, Nomoto T, Hayakawa S. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol. 2007; 13 2179-2182
120 Misra S P, Dwivedi M. Large-diameter balloon dilation after endoscopic sphincterotomy for removal of difficult bile duct stones. Endoscopy. 2008; 40 209-213
121 Heo J H, Kang D H, Jung H J. et al . Endoscopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones. Gastrointest Endosc. 2007; 66 720-726; quiz 768, 771
122 Kawamoto M, Geenen J, Omari T. et al . Sleeve sphincter of Oddi (SO) manometry: a new method for characterizing the motility of the sphincter of Oddi. J Hepatobiliary Pancreat Surg. 2008; 15 391-396
123 Frenz M B, Wehrmann T. Solid state biliary manometry catheter: impact on diagnosis and post-study pancreatitis. Curr Gastroenterol Rep. 2007; 9 171-174
124 Craig A G, Omari T, Lingenfelser T. et al . Development of a sleeve sensor for measurement of sphincter of Oddi motility. Endoscopy. 2001; 33 651-657
125 Sherman S, Troiano F P, Hawes R H, Lehman G A. Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with use of a modified aspirating catheter. Gastrointest Endosc. 1990; 36 462-466
126 Draganov P, Kowalczyk L, Forsmark C. Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc. 2009; 70 92-95
127 Wehrmann T, Stergiou N, Schmitt T, Dietrich C F, Seifert H. Reduced risk for pancreatitis after endoscopic microtransducer manometry of the sphincter of Oddi: a randomized comparison with the perfusion manometry technique. Endoscopy. 2003; 35 472-477
128 Sherman S, Hawes R H, Troiano F P, Lehman G A. Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter. Gastrointest Endosc. 1992; 38 347-350
129 Singh P, Das A, Isenberg G. et al . Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc. 2004; 60 544-550
130 Sofuni A, Maguchi H, Itoi T. et al . Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol. 2007; 5 1339-1346
131 Chahal P, Tarnasky P, Petersen B. et al . Short 5Fr vs long 3Fr pancreatic stents in patients at high risk for post- endoscopic cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2009; 7 834-839
132 Fehmi S MA, Schoenfeld P S, Scheiman J M. et al . 5 Fr prophylactic pancreatic stents are easier to place and require fewer guide wires than 3 Fr stents. Gastrointest Endosc. 2008; 67 AB328-AB329
133 Smith M T, Sherman S, Ikenberry S O, Hawes R H, Lehman G A. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc. 1996; 44 268-275
134 Das A, Singh P, Sivak M V, Chak A. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc. 2007; 65 960-968
135 Freeman M L, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc. 2004; 59 8-14
136 Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc. 2006; 64 45-52
137 Dumonceau J M, Rigaux J, Kahaleh M. et al . Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc. 2010; 71 934-939

J.-M. DumonceauMD, PhD

Division of Gastroenterology and Hepatology
Geneva University Hospitals

rue Micheli-du-Crest 24
1205 Geneva
Switzerland

Fax: +41-22-3729366

Email: jmdumonceau@hotmail.com